[ad_1]
Published in Drug and Alcohol Dependence Reports, the study shows that identifying and overcoming barriers to appropriate use of medications to treat opioid use disorder (OUD) is critical to address the opioid crisis
Richmond, Va., Aug. 25, 2022 /PRNewswire/ — Indivior PLC (LON: INDV) announced today a new analysis highlighting the results of an exploratory study analyzing real-world data of US distribution patterns of buprenorphine extended-release (BUP-XR also referred to as RBP-6000 or SUBLOCADE®), a monthly subcutaneous injection of buprenorphine that was approved by the FDA in November 2017 for the treatment of moderate-to-severe OUD,1 within organized health systems (OHS). The study titled “The Introduction of a Novel Formulation of Buprenorphine Into Organized Health Systems” was published in the August online issue of Drug and Alcohol Dependence Reports, a peer-reviewed journal.
This exploratory study used real-world evidence to identify barriers to medications for opioid use disorder (MOUD) treatment by analyzing the distribution patterns of BUP-XR over the 12-month period from July 2019 to July 2020 across four OHS subtypes including Integrated Delivery Networks (IDNs), Veterans Health Administration (VHA), Criminal Justice System (CJS), and Indian Health Services (IHS).
In addition to assessing the national distribution patterns of BUP-XR across OHS subtypes, this study also evaluated the distribution of BUP-XR within each subtype over time.
Overall, the distribution of BUP-XR as a treatment option for patients with OUD increased within OHS but occurred at different rates across OHS subtypes. Numerous barriers within each OHS subtype impede access to MOUD, despite evidence in support of their effectiveness in reducing morbidity and mortality from OUD, increasing treatment retention, and improving the quality of life of patients with OUD.
“Removing system-level, provider-level, and local-level barriers to quality treatment and integrating OUD treatment into routine care and other settings are critical steps to ensuring access to evidence-based MOUD and represent a cornerstone of the opioid crisis response in the United States,” said Christian HeidbrederPhD, Chief Scientific Officer, Indivior.
Study findings within each OHS Subtype:
Integrated Delivery Networks
- IDNs contributed a significant percentage of the overall national distribution of BUP-XR and showed higher BUP-XR growth over time compared with other …
Full story available on Benzinga.com
[ad_2]
Source link
